acasunlimab

Acasunlimab sees a surge in engagements driven by X activity, though overall mentions and creator activity have recently declined. The bispecific antibody is showing strong long-term community growth despite short-term fluctuations.

About acasunlimab

Acasunlimab is a bispecific antibody developed for cancer immunotherapy.

Engagements: [--] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [---]
[--] Week: [--] -42%
[--] Month: [---] -98%
[--] Months: [------] +144%
[--] Year: [------] -56%
1-Year High: [-----] on 2025-12-29
1-Year Low: [--] on 2025-04-07

Engagements by network (24h): News: [--] X: [--]

Mentions: [--] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [--] -27%
[--] Month: [--] -49%
[--] Months: [---] +419%
[--] Year: [---] +15%
1-Year High: [--] on 2025-09-25
1-Year Low: [--] on 2025-02-18

Mentions by network (24h): News: [--] X: [--]

Creators: [--] (24h)

Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning acasunlimab in the last [--] hours which is down 50% from [--] in the previous [--] hours Daily Average: [--]
[--] Week: [--] -27%
[--] Month: [--] -43%
[--] Months: [--] +336%
[--] Year: [--] +13%
1-Year High: [--] on 2025-12-30
1-Year Low: [--] on 2025-02-18

Sentiment: %

Sentiment 24-Hour Time-Series Raw Data
Current Value: %
Daily Average: 82%
[--] Week: 67% no change
[--] Month: 67% -8%
[--] Months: 67% +7%
[--] Year: 67% -33%
1-Year High: 100% on 2025-10-07
1-Year Low: 33% on 2025-10-03

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing